AnaptysBio reports positive Phase 3 GEMINI-1 trial for imsidolimab in GPP; 53.3% vs 13.3% placebo at Week 4

ANAPTYSBIO, INC

53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).
No SAEs or severe AEs in imsidolimab-treated patients; low infection rate vs placebo.
Only 3.3% had detectable non-neutralizing ADA.
Plans to file BLA with FDA by Q3 2024 and out-license imsidolimab in 2024.
Comprehensive data from GEMINI-1 and top-line GEMINI-2 expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.